Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?

David K. Shay; Benjamin J. Ridenhour

Download: PDF | Citation | XML
EzReprint New & improved!

Published in the June 2009 Issue of PLoS Medicine

Metrics info

Average Rating (0 User Ratings)

- Currently 0/5 Stars.
Rate This Article

Rate This Article

Please follow our guidelines for rating and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:

Remarks that could be interpreted as allegations of misconduct
Unsupported assertions or statements
Inflammatory or insulting language

Compose Your Annotation

Rating

Enter your comment title Enter your comment

Declare any competing interests.

No, I don't have any competing interests to declare.
Yes, I have competing interests to declare (enter below):

Ratings can include the following markup tags:

Emphasis: ''italic'' '''bold''' '''''bold italic'''''

Other: ^^^superscript^^ ~~_subscript~~

Metrics info

Average Rating (0 User Ratings)

Related Content

Share this Article info

Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?

Related Articles info

Related PLoS Articles

Related Articles on the Web

Bookmarked in

Related Blog Posts info

Trackbacks

Rate This Article